National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

ADH-1
A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Exherin



Previous:adenovirus encoding human aquaporin-1, adenovirus encoding recombinant human endostatin, adenovirus HER2-transduced autologous dendritic cell vaccine, adenovirus vector, adenovirus-interferon-gamma TG1042
Next:adipose-derived regenerative cells, adozelesin, Adriamycin PFS, Adriamycin RDF, Adrucil

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov